Royalty Pharma plc - Ordinary Shares - Class A Aktie News

Royalty Pharma remains a Buy supported by strong execution and upward guidance revision. RPRX trades at a significant valuation discount to biopharma peers, with 86% of its portfolio in approved therapies and robust free cash flow growth. Management projects 11–14% portfolio receipts CAGR through 2030, exceeding consensus, and demonstrates disciplined capital allocation with M&A capability.

Royalty Pharma plc (NASDAQ:RPRX ) Investor Day 2025 Conference September 11, 2025 8:30 AM EDT Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman of the Board & CEO Ashwin Pai - Executive Vice President of Investments Christopher Hite - Vice Chairman & Executive VP Brienne Kugler - Senior VP of Research & Investments...

On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma's platform value Investments since 2020 on track to deliver mid-teens unlevered IRR, ahead of target Achieved 15% Return on Inves...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive analysis of the current dynamics, growth drivers and outlook for biopharma royalties. The full report is av...

Royalty Pharma plc (NASDAQ:RPRX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT Company Participants Pablo Legorreta - Founder, Chairman of the Board & CEO Terrance Coyne - Executive VP & CFO Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):

NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab.